Granted Patent
B2
US 12,246,030 · App. 18/167,984 · Granted Mar 11, 2025
Methods for therapeutic administration of messenger ribonucleic acid drugs
Inventors:
Stephen Hoge (Cambridge, MA); Tirtha Chakraborty (Cambridge, MA); Gilles Besin (Cambridge, MA); Ruchi Jain (Cambridge, MA)
Assignee:
ModernaTX, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit ADA or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.
Claims (32)
1. A messenger RNA (mRNA) encoding a polypeptide of interest, wherein the mRNA comprises a 3′ untranslated region (UTR) comprising at least one miR-142 binding site and at least one miR-126 binding site, and wherein the mRNA comprises one or more modified nucleobases.
2. The mRNA of claim 1 , wherein the 3′UTR comprises 2, 3, or 4 miR-142 binding sites.
3. The mRNA of claim 1 , wherein the 3′UTR comprises 2, 3, or 4 miR-126 binding sites.
4. The mRNA of claim 1 , wherein the at least one miR-142 binding site is a miR-142-3p binding site.
5. The mRNA of claim 1 , wherein the at least one miR-142 binding site is a miR-142-5p binding site.
6. The mRNA of claim 1 , wherein the at least one miR-126 binding site a miR-126-3p binding site.
7. The mRNA of claim 1 , wherein the at least one miR-126 binding site is a miR-126-5p binding site.
8. The mRNA of claim 1 , wherein the one or more modified nucleobases is selected from pseudouridine (ψ), pseudouridine (ψ) and 5-methyl-cytidine (m 5 C), 1-methyl-pseudouridine (m 1 ψ), 1-methyl-pseudouridine (m 1 ψ) and 5-methyl-cytidine (m 5 C), 2-thiouridine (s 2 U), 2-thiouridine and 5-methyl-cytidine (m 5 C), 5-methoxy-uridine (mo 5 U), 5-methoxy-uridine (mo 5 U) and 5-methyl-cytidine (m 5 C), 2′-O-methyl uridine, 2′-O-methyl uridine and 5-methyl-cytidine (m 5 C), N6-methyl-adenosine (m 6 A) or N6-methyl-adenosine (m 6 A) and 5-methyl-cytidine (m 5 C).
9. The mRNA of claim 1 , wherein all uracil nucleobases in the mRNA are modified uracil nucleobases.
10. The mRNA of claim 9 , wherein the modified uracil nucleobases are selected from pseudouridines (ψ), 1-methyl-pseudouridines (m 1 ψ), and 5-methoxy-uridines (mo 5 U).
11. The mRNA of claim 9 , wherein the modified uracil nucleobases are 1-methyl-pseudouridines (m 1 ψ).
12. The mRNA of claim 1 , wherein all cytosine nucleobases in the mRNA are modified cytosine nucleobases.
13. The mRNA of claim 12 , wherein the modified cytosine nucleobases are 5-methyl-cytidine.
14. The mRNA of claim 1 , wherein the polypeptide of interest is a therapeutic protein, cytokine, growth factor, antibody or fusion protein.
15. A mRNA encoding a polypeptide of interest, wherein the mRNA comprises a 3′ UTR comprising at least one miR-142-3p binding site and at least one miR-126-3p binding site, and wherein the mRNA comprises one or more modified nucleobases.
16. The mRNA of claim 15 , wherein the 3′UTR comprises 2, 3, or 4 miR-142-3p binding sites.
17. The mRNA of claim 15 , wherein the 3′UTR comprises 2, 3, or 4 miR-126-3p binding sites.
18. The mRNA of claim 15 , wherein the miR-142-3p binding site comprises the sequence of SEQ ID NO: 3.
19. The mRNA of claim 15 , wherein the miR-126-3p binding site comprises the sequence of SEQ ID NO: 26.
20. The mRNA of claim 15 , wherein the one or more modified nucleobases is selected from pseudouridine (ψ), pseudouridine (ψ) and 5-methyl-cytidine (m 5 C), 1-methyl-pseudouridine (m 1 ψ), 1-methyl-pseudouridine (m 1 ψ) and 5-methyl-cytidine (m 5 C), 2-thiouridine (s 2 U), 2-thiouridine and 5-methyl-cytidine (m 5 C), 5-methoxy-uridine (mo 5 U), 5-methoxy-uridine (mo 5 U) and 5-methyl-cytidine (m 5 C), 2′-O-methyl uridine, 2′-O-methyl uridine and 5-methyl-cytidine (m 5 C), N6-methyl-adenosine (m 6 A) or N6-methyl-adenosine (m 6 A) and 5-methyl-cytidine (m 5 C).
21. The mRNA of claim 15 , wherein all uracil nucleobases in the mRNA are modified uracil nucleobases.
22. The mRNA of claim 21 , wherein the modified uracil nucleobases are selected from pseudouridines (ψ), 1-methyl-pseudouridines (m 1 ψ), and 5-methoxy-uridines (mo 5 U).
23. The mRNA of claim 21 , wherein the modified uracil nucleobases are 1-methyl-pseudouridines (m 1 ψ).
24. The mRNA of claim 15 , wherein all cytosine nucleobases in the mRNA are modified cytosine nucleobases.
25. The mRNA of claim 24 , wherein the modified cytosine nucleobases are 5-methyl-cytidine.
26. The mRNA of claim 15 , wherein the polypeptide of interest is a therapeutic protein, cytokine, growth factor, antibody or fusion protein.
27. A lipid nanoparticle comprising the mRNA of claim 1 , wherein the lipid nanoparticle comprises an ionizable lipid, a structural lipid, a phospholipid, and a PEG lipid.
28. A pharmaceutical composition comprising the lipid nanoparticle of claim 27 and a pharmaceutically acceptable carrier, diluent or excipient.
29. A lipid nanoparticle comprising the mRNA of claim 15 , wherein the lipid nanoparticle comprises an ionizable lipid, a structural lipid, a phospholipid, and a PEG lipid.
30. A pharmaceutical composition comprising the lipid nanoparticle of claim 29 and a pharmaceutically acceptable carrier, diluent or excipient.
31. The mRNA of claim 15 , wherein the 3′UTR comprises one miR-142-3p binding site comprising the sequence of SEQ ID NO: 3 and one miR-126-3p binding site comprising the sequence of SEQ ID NO: 26.
32. The mRNA of claim 31 , wherein all uracil nucleobases in the mRNA are modified uracil nucleobases, and wherein the modified uracil nucleobases are 1-methyl-pseudouridines (m1ψ).
Assignments (2)
SECURITY INTEREST
Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 13, 2023
From: HOGE, STEPHEN; CHAKRABORTY, TIRTHA; BESIN, GILLES; JAIN, RUCHI
To: MODERNATX, INC.
Reel/Frame 062963/0440 →
Continuity (11)
Continuation
15761220
Provisional Application
62350149
· Jun 14, 2016
Provisional Application
62338388
· May 18, 2016
Provisional Application
62338385
· May 18, 2016
Provisional Application
62338386
· May 18, 2016
Provisional Application
62317366
· Apr 1, 2016
Provisional Application
62317271
· Apr 1, 2016
Provisional Application
62317268
· Apr 1, 2016
Provisional Application
62237462
· Oct 5, 2015
References Cited (400)
US 5489677A
· Sanghvi et al.
· 1996
[cited by applicant]
US 6310197B1
· Rogers
· 2001
[cited by applicant]
US 6849405B2
· Rogers
· 2005
[cited by applicant]
US 7183395B2
· Mauro et al.
· 2007
[cited by applicant]
US 7456273B2
· Mauro et al.
· 2008
[cited by applicant]
US 8039214B2
· Dahl et al.
· 2011
[cited by applicant]
US 8058069B2
· Yaworski et al.
· 2011
[cited by applicant]
US 8158601B2
· Chen et al.
· 2012
[cited by applicant]
US 8217016B2
· Hoerr et al.
· 2012
[cited by applicant]
US 8278036B2
· Kariko et al.
· 2012
[cited by applicant]
US 8329887B2
· Dahl et al.
· 2012
[cited by applicant]
US 8354513B2
· Mikesell et al.
· 2013
[cited by applicant]
US 8519110B2
· Kowalska et al.
· 2013
[cited by applicant]
US 8664194B2
· de Fougerolles et al.
· 2014
[cited by applicant]
US 8680069B2
· de Fougerolles et al.
· 2014
[cited by applicant]
US 8691750B2
· Constien et al.
· 2014
[cited by applicant]
US 8691966B2
· Kariko et al.
· 2014
[cited by applicant]
US 8710200B2
· Schrum et al.
· 2014
[cited by applicant]
US 8716465B2
· Rossi et al.
· 2014
[cited by applicant]
US 8748089B2
· Kariko et al.
· 2014
[cited by applicant]
US 8754062B2
· de Fougerolles et al.
· 2014
[cited by applicant]
US 8802438B2
· Rossi et al.
· 2014
[cited by applicant]
US 8808982B2
· Dahl et al.
· 2014
[cited by applicant]
US 8822663B2
· Schrum et al.
· 2014
[cited by applicant]
US 8835108B2
· Kariko et al.
· 2014
[cited by applicant]
US 8846348B2
· Jendrisak et al.
· 2014
[cited by applicant]
US 8853179B2
· Mauro et al.
· 2014
[cited by applicant]
US 8853377B2
· Guild et al.
· 2014
[cited by applicant]
US 8871230B2
· Rudolph et al.
· 2014
[cited by applicant]
US 8883506B2
· Rossi et al.
· 2014
[cited by applicant]
US 8999380B2
· Bancel et al.
· 2015
[cited by applicant]
US 9597380B2
· Chakraborty et al.
· 2017
[cited by applicant]
US 9751925B2
· Hoge et al.
· 2017
[cited by applicant]
US 20030192068A1
· DeBoer et al.
· 2003
[cited by applicant]
US 20050065333A1
· Seth
· 2005
[cited by applicant]
US 20060188490A1
· Hoerr et al.
· 2006
[cited by applicant]
US 20060247195A1
· Ray
· 2006
[cited by applicant]
US 20080267873A1
· Hoerr et al.
· 2008
[cited by applicant]
US 20090093049A1
· Mauro et al.
· 2009
[cited by applicant]
US 20100047261A1
· Hoerr et al.
· 2010
[cited by applicant]
US 20100196357A1
· Huang et al.
· 2010
[cited by applicant]
US 20100239608A1
· Von Der Mulbe et al.
· 2010
[cited by applicant]
US 20110045022A1
· Tsai
· 2011
[cited by applicant]
US 20110065103A1
· Sahin et al.
· 2011
[cited by applicant]
US 20110077287A1
· Von Der Mulbe et al.
· 2011
[cited by applicant]
US 20110086904A1
· Russell
· 2011
[cited by applicant]
US 20110151444A1
· Albers et al.
· 2011
[cited by applicant]
US 20110244026A1
· Guild et al.
· 2011
[cited by applicant]
US 20110247090A1
· Reed
· 2011
[cited by applicant]
US 20110250237A1
· O'Hagan et al.
· 2011
[cited by applicant]
US 20110300205A1
· Geall et al.
· 2011
[cited by applicant]
US 20110311472A1
· Hoerr et al.
· 2011
[cited by applicant]
US 20120027813A1
· Podda et al.
· 2012
[cited by applicant]
US 20120195936A1
· Rudolph
· 2012
[cited by examiner]
US 20120237975A1
· Schrum et al.
· 2012
[cited by applicant]
US 20120301955A1
· Thomas et al.
· 2012
[cited by applicant]
US 20130102034A1
· Schrum
· 2013
[cited by applicant]
US 20130123481A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130156849A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130165504A1
· Bancel et al.
· 2013
[cited by applicant]
US 20130171241A1
· Geall
· 2013
[cited by applicant]
US 20130177581A1
· Mauro et al.
· 2013
[cited by applicant]
US 20130189351A1
· Geall
· 2013
[cited by applicant]
US 20130189741A1
· Meis et al.
· 2013
[cited by applicant]
US 20130202684A1
· Geall et al.
· 2013
[cited by applicant]
US 20130236974A1
· de Fougerolles
· 2013
[cited by applicant]
US 20130237592A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130237593A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130244279A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130244282A1
· Schrum et al.
· 2013
[cited by applicant]
US 20130245096A1
· Abitbol
· 2013
[cited by applicant]
US 20130245103A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130245106A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130245107A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130266640A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20140010861A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140030292A1
· Franti et al.
· 2014
[cited by applicant]
US 20140113959A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140141037A1
· Swanson et al.
· 2014
[cited by applicant]
US 20140141070A1
· Geall et al.
· 2014
[cited by applicant]
US 20140148502A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140155472A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140155473A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140155474A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140155475A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140171485A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140178429A1
· Tsai
· 2014
[cited by applicant]
US 20140179771A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140193482A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140193484A1
· Bertholet Girardin et al.
· 2014
[cited by applicant]
US 20140194494A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140200261A1
· Hoge et al.
· 2014
[cited by applicant]
US 20140200263A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140200264A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140206752A1
· Afeyan et al.
· 2014
[cited by applicant]
US 20140206753A1
· Guild et al.
· 2014
[cited by applicant]
US 20140206755A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140206852A1
· Hoge et al.
· 2014
[cited by applicant]
US 20140248312A1
· Rappuoli et al.
· 2014
[cited by applicant]
US 20140248314A1
· Swanson et al.
· 2014
[cited by applicant]
US 20140255467A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140255468A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140255472A1
· Geall et al.
· 2014
[cited by applicant]
US 20140271829A1
· Lilja et al.
· 2014
[cited by applicant]
US 20140275229A1
· Bancel et al.
· 2014
[cited by applicant]
US 20140294940A1
· Guild et al.
· 2014
[cited by applicant]
US 20140343129A1
· de Fougerolles et al.
· 2014
[cited by applicant]
US 20140370545A1
· Mauro et al.
· 2014
[cited by applicant]
US 20140371302A1
· Afeyan et al.
· 2014
[cited by applicant]
US 20140378538A1
· Bancel
· 2014
[cited by applicant]
US 20150005372A1
· Hoge et al.
· 2015
[cited by applicant]
US 20150030576A1
· Bancel
· 2015
[cited by applicant]
US 20150044277A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150050354A1
· Bouchon et al.
· 2015
[cited by applicant]
US 20150051268A1
· Bancel et al.
· 2015
[cited by applicant]
US 20150141499A1
· Bancel et al.
· 2015
[cited by applicant]
US 20160022840A1
· Chakraborty et al.
· 2016
[cited by applicant]
US 20170202979A1
· Chakraborty et al.
· 2017
[cited by applicant]
US 20170252461A1
· Chakraborty et al.
· 2017
[cited by applicant]
US 20170362605A1
· Chakraborty
· 2017
[cited by applicant]
US 20190185529A1
· Hoge et al.
· 2019
[cited by applicant]
CA 2795695A1
· 2011
[cited by applicant]
EP 2221371A1
· 2010
[cited by applicant]
EP 2246422A1
· 2010
[cited by applicant]
EP 2700708A2
· 2014
[cited by applicant]
WO WO1999014346A2
· 1999
[cited by applicant]
WO WO1999024595A1
· 1999
[cited by applicant]
WO WO2001055369A1
· 2001
[cited by applicant]
WO WO2004076622A2
· 2004
[cited by applicant]
WO WO2005005622A2
· 2005
[cited by applicant]
WO WO2006111512A1
· 2006
[cited by applicant]
WO WO2006128245A1
· 2006
[cited by applicant]
WO WO2007000668A2
· 2007
[cited by applicant]
WO WO2007024708A2
· 2007
[cited by applicant]
WO WO2007064952A2
· 2007
[cited by applicant]
WO WO2007044627A3
· 2007
[cited by applicant]
WO WO2007025008A3
· 2007
[cited by applicant]
WO WO2008052770A2
· 2008
[cited by applicant]
WO WO2008083949A2
· 2008
[cited by applicant]
WO WO2008091799A3
· 2008
[cited by applicant]
WO WO2008140615A2
· 2008
[cited by applicant]
WO WO2009015071A1
· 2009
[cited by applicant]
WO WO2009075886A1
· 2009
[cited by applicant]
WO WO2009077134A2
· 2009
[cited by applicant]
WO WO2009127230A1
· 2009
[cited by applicant]
WO WO2010017510A1
· 2010
[cited by applicant]
WO WO2010042877A1
· 2010
[cited by applicant]
WO WO2010054406A1
· 2010
[cited by applicant]
WO WO2010055413A1
· 2010
[cited by applicant]
WO WO2010088537A2
· 2010
[cited by applicant]
WO WO2010098861A1
· 2010
[cited by applicant]
WO WO2010125471A2
· 2010
[cited by applicant]
WO WO2010027903A8
· 2010
[cited by applicant]
WO WO2010129709A1
· 2010
[cited by applicant]
WO WO2011012316A3
· 2011
[cited by applicant]
WO WO2011005786A3
· 2011
[cited by applicant]
WO WO2011025566A1
· 2011
[cited by applicant]
WO WO2011068810A1
· 2011
[cited by applicant]
WO WO2011071931A2
· 2011
[cited by applicant]
WO WO2011071936A2
· 2011
[cited by applicant]
WO WO2011088309A1
· 2011
[cited by applicant]
WO WO2011130624A2
· 2011
[cited by applicant]
WO WO2012019168A2
· 2012
[cited by applicant]
WO WO2012019630A1
· 2012
[cited by applicant]
WO WO2012009644A3
· 2012
[cited by applicant]
WO WO2012045075A1
· 2012
[cited by applicant]
WO WO2012045082A2
· 2012
[cited by applicant]
WO WO2012056440A1
· 2012
[cited by applicant]
WO WO2012089338A1
· 2012
[cited by applicant]
WO WO2012135805A2
· 2012
[cited by applicant]
WO WO2012138453A1
· 2012
[cited by applicant]
WO WO2012170889A1
· 2012
[cited by applicant]
WO WO2012170930A1
· 2012
[cited by applicant]
WO WO2013039857A1
· 2013
[cited by applicant]
WO WO2013090186A1
· 2013
[cited by applicant]
WO WO2013090648A1
· 2013
[cited by examiner]
WO WO2013103659A1
· 2013
[cited by applicant]
WO WO2013109713A1
· 2013
[cited by applicant]
WO WO2013120497A1
· 2013
[cited by applicant]
WO WO2013120498A1
· 2013
[cited by applicant]
WO WO2013120499A1
· 2013
[cited by applicant]
WO WO2013120500A1
· 2013
[cited by applicant]
WO WO2013120626A1
· 2013
[cited by applicant]
WO WO2013120627A1
· 2013
[cited by applicant]
WO WO2013120628A1
· 2013
[cited by applicant]
WO WO2013120629A1
· 2013
[cited by applicant]
WO WO2013134349A1
· 2013
[cited by applicant]
WO WO2013131143A1
· 2013
[cited by applicant]
WO WO2013151666A2
· 2013
[cited by applicant]
WO WO2013151663A1
· 2013
[cited by applicant]
WO WO2013151664A1
· 2013
[cited by applicant]
WO WO2013151665A2
· 2013
[cited by applicant]
WO WO2013151667A1
· 2013
[cited by applicant]
WO WO2013151668A2
· 2013
[cited by applicant]
WO WO2013151669A1
· 2013
[cited by applicant]
WO WO2013151670A2
· 2013
[cited by applicant]
WO WO2013151671A1
· 2013
[cited by applicant]
WO WO2013151672A2
· 2013
[cited by applicant]
WO WO2013151736A2
· 2013
[cited by applicant]
WO WO2014028429A2
· 2014
[cited by applicant]
WO WO2014081507A1
· 2014
[cited by applicant]
WO WO2014093574A1
· 2014
[cited by applicant]
WO WO2014093924A1
· 2014
[cited by applicant]
WO WO2014113089A2
· 2014
[cited by applicant]
WO WO2014144039A1
· 2014
[cited by applicant]
WO WO2014144711A1
· 2014
[cited by applicant]
WO WO2014144767A1
· 2014
[cited by applicant]
WO WO2014152027A1
· 2014
[cited by applicant]
WO WO2014152030A1
· 2014
[cited by applicant]
WO WO2014152031A1
· 2014
[cited by applicant]
WO WO2014152211A1
· 2014
[cited by applicant]
WO WO2014152540A1
· 2014
[cited by applicant]
WO WO2014158795A1
· 2014
[cited by applicant]
WO WO2014159813A1
· 2014
[cited by applicant]
WO WO2014164253A1
· 2014
[cited by applicant]
WO WO2014140856A3
· 2014
[cited by applicant]
WO WO2015006747A2
· 2015
[cited by applicant]
WO WO2015007871A3
· 2015
[cited by applicant]
WO WO2015034925A1
· 2015
[cited by applicant]
WO WO2015034928A1
· 2015
[cited by applicant]
WO WO2015038892A1
· 2015
[cited by applicant]
WO WO2015048744A2
· 2015
[cited by applicant]
WO WO2015051173A2
· 2015
[cited by applicant]
WO WO2015051214A1
· 2015
[cited by applicant]
WO WO2015058069A1
· 2015
[cited by applicant]
WO WO2015105926A1
· 2015
[cited by applicant]
WO WO2015073884A3
· 2015
[cited by applicant]
WO WO2016011306A3
· 2016
[cited by applicant]
WO WO2016100812A1
· 2016
[cited by applicant]
WO WO2016170176A1
· 2016
[cited by applicant]
WO WO2017112943A1
· 2017
[cited by applicant]
Newby et al. (PNAS, 2002, 99, 20, 12697-12702).
[cited by examiner]
Kormann et al. (Nature Biotechnology, 29, 2, 2011, 154-159).
[cited by examiner]
Tavernier et al. (Journal of Controlled Release 150 (2011) 238-247).
[cited by examiner]
U.S. Appl. No. 17/127,435, filed Dec. 18, 2020, Chakraborty et al.
[cited by applicant]
U.S. Appl. No. 17/162,061, filed Jan. 29, 2021, Hoge et al.
[cited by applicant]
Anadarini, S. et al., “Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts,” Cancer Research, vol. 64:3281-3287 (2004).
[cited by applicant]
Anderson, B.R. et al., “Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation,” Nucleic Acids Research, vol. 38(17):5884-5892 (2010).
[cited by applicant]
Annoni, A. et al., “In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance,” Blood, vol. 114: 5152-5161 (2009).
[cited by applicant]
Beilharz, T. et al., “Widespread use of poly(A) tail length control to accentuate expression of the yeast transcriptome,” RNA, vol. 13(7): 982-997 (2007) Abstract.
[cited by applicant]
Blum, E. et al., “Polyadenylation Promotes Degradation of 3′-Structured RNA by the <i>
[cited by applicant]
Bolukbasi, M.F. et al., “miR-1289 and “Zipcode”-like Sequence Enrich mRNAs in Microvesicles,” Molecular Therapy—Nucleic Acids, vol. 1, e10: 10 pages (2012) doi:10.1038/mtna.2011.2.
[cited by applicant]
Brown, B.D. et al., “Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state”, Nature Biotechnology, vol. 25:1457-1467 (2007).
[cited by applicant]
Brown, J.A. et al., “Formation of triple-helical structures by the 3′-end sequences of MALAT1 and MEN noncoding RNAs,” PNAS, vol. 109 (47):19202-19207 (2012).
[cited by applicant]
Cawood, R. et al., “Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells,” PLOS Pathogens, Public Library of Science, vol. 5(5): e1000440: …
[cited by applicant]
Chappell, S. A., et al. “Biochemical and functional analysis of a 9-nt RNA sequence that affects translation efficiency in eukaryotic cells,” PNAS, vol. 101 (26): 9590-9594 (2004).
[cited by applicant]
Collins, F. et al., “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences, ” PNAS, vol. 99(26):16899-16903 (2002).
[cited by applicant]
Dannull, J. et al., “Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand,” Blood, vol. 105 (8):3206-3213 (2004).
[cited by applicant]
Direct Submission Submitted (Feb. 5, 2001) National Institutes of Health, Mammalian Gene Collection (MGC), Bethesda, MD 20892-2590, USA <i>
[cited by applicant]
Ebert, M.S., et al., “MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells,” Nat. Methods, vol. 4:721-726. (2007).
[cited by applicant]
Extended European Search Report, European Application No. 14780126, dated Nov. 8, 2016, 11 pages.
[cited by applicant]
Extended European Search Report, European Application No. 15871164.8, dated May 25, 2018, 6 pages.
[cited by applicant]
Extended European Search Report, European Application No. 18179340.7, dated Nov. 9, 2018, 14 pages.
[cited by applicant]
Fan, X. C., et al., “Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs,” The EMBO Journal, vol. 17(12):3448-3460 (1998).
[cited by applicant]
Helm, M., “Post-transcriptional nucleotide modification and alternative folding of RNA,” Nucleic Acids Research, vol. 34(2): 721-733 (2006).
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2013/062531, dated Jul. 21, 2015, 19 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2013/062943, dated May 26, 2015, 11 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2014/021522, dated Sep. 15, 2015, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2015/040835, dated Jan. 17, 2017, 9 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2015/066662, dated Jun. 20, 2017, 7 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2016/055582, dated Apr. 10, 2018, 8 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/ US2015/40835, dated Jan. 4, 2016, 21 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2013/062531, dated Jul. 3, 2014, 30 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2013/062943, dated Jan. 7, 2014, 17 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2014/021522, dated Sep. 4, 2014, 13 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2014/053904, dated Feb. 11, 2015, 19 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2014/053907, dated Dec. 18, 2014, 9 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2015/066662, dated Mar. 7, 2016, 11 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2016/055582, dated Mar. 13, 2017, 14 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2016/068552, dated Mar. 21, 2017, 6 pages.
[cited by applicant]
Kariko, K. et al., “Generating the optimal mRNA for therapy: HPLC, purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA,” Nucleic Acids Research, vol. 39 (21):…
[cited by applicant]
Kariko K. et al., “Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability,” Molecular Therapy, Nature Publishing Group, vol. 16 (11)…
[cited by applicant]
Kariko, K. et al., “Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA,” Immunity, vol. 23: 165-175 (2005).
[cited by applicant]
Kedde, M. et al., “A Pumilio-induced RNA structure switch in p27-3′ UTR controls miR-221 and miR-222 accessibility,” Nature Cell Biology, vol. 10(12)1014-1020 (2010).
[cited by applicant]
Kore, A.R. et al., “Synthesis and biological validation of N7-(4-chlorophenoxyethyl) substituted dinucleotide cap analogs for mRNA translation,” Bioorganic & Medicinal Chemistry, vol. 21:4570-4574 (2013).
[cited by applicant]
Kormann, M.S. et al., “Expression of therapeutic proteins after delivery of chemically modified mRNA in mice,” Nature Biotechnology, vol. 29(2):154-159 (2011).
[cited by applicant]
Kron, M. et al., “miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens,” Molecular Therapy, vol. 19(8):1547-1557 (2011).
[cited by applicant]
Lennox, KA, et al., “Chemical modification and design of anti-miRNA oligonucleotides,” Gene Therapy, vol. 18 (12):1111-1120 (2011).
[cited by applicant]
Leppek, K., et al., “Roquin Promotes Constitutive mRNA Decay via a Conserved Class of Stem-Loop Recognition Motifs,” Cell, vol. 153: 869-881 (2013).
[cited by applicant]
Limbach, PA., et al., “Summary: the modified nucleosides of RNA,” Nucleic Acids Research, vol. 22 (12): 2183-2196 (1994).
[cited by applicant]
Link, et al. “Structure of <i>
[cited by applicant]
Lorenz, C. et al., “Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway,” RNA Biology, vol. 8(4):627-636 (2011).
[cited by applicant]
Lytle, J.R., et al., “Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR,” PNAS, vol. 104(23): 9667-9672 (2007).
[cited by applicant]
Meijer, H.A., et al., “Translational Repression and eIF4A2 Activity Are Critical for MicroRNA-Mediated Gene Regulation,” Science vol. 340: 82-85 (2013).
[cited by applicant]
Nemani, M. et al., “Activation of the human homologue of the <i>
[cited by applicant]
Panek, J. et al., “An evolutionary conserved pattern of 18S rRNA sequence complementarity to mRNA 5′ UTRs and its implications for eukaryotic gene translation regulation,” Nucleic Acids Research, vol. 41(16):7625-7634 (…
[cited by applicant]
Partial Supplementary European Search Report, European Application No. 15821578.0, dated May 30, 2018, 12 pages.
[cited by applicant]
Peart, N. et al., “Non-mRNA 3′ end formation: how the other half lives,” Wiley Interdiscip Rev RNA, vol. 4(5):491-506 (2013) doi: 10.1002/wrna.1174. Epub Jun. 10, 2013.
[cited by applicant]
Piccinini, A. et al., “Illustrating the interplay between the extracellular matrix and microRNAs,” Int. J.Exp. Path., vol. 95:158-180 (2014).
[cited by applicant]
Pichard, V. et al., “Specific Micro RNA-Regulated TetR-KRAB Transcriptional Control of Transgene Expression in Viral Vector-Transduced Cells,” PLOS One, vol. 7(12): e51952: 10 pages (2012).
[cited by applicant]
Probst J et al., “Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent,” Gene Therapy, Nature Publishing Group, vol. 14: 1175-1180 (2007).
[cited by applicant]
Rotondaro, L. et al., “Efficiency of different viral promoters in directing gene expression in mammalian cells: effect of 3′-untranslated sequences,” Gene, vol. 168(2):195-198 (1996).
[cited by applicant]
Rozenski, J., “The RNA Modification Database: 1999 update,” Nucleic Acids Research, vol. 27(1):196-197 (1999).
[cited by applicant]
Sahin, U. et al., “mRNA-based therapeutics—developing a new class of drugs,” Nature Reviews Drug Discovery, vol. 13(10)759-780 (2014).
[cited by applicant]
Savino, M. et al., “The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy,” PLOS One, vol. 6(7): e22284 (2011).
[cited by applicant]
Singh, R. et al., “Nanoengineering artificial lipid envelopes around adenovirus by self-assembly,” ACS Nano, vol. 2(5):1040-1050 (2008).
[cited by applicant]
Smirnov, D.A. et al., “ATM Gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs”, The American Journal of Human Genetics, vol. 83: 243-253 (2008).
[cited by applicant]
Soucek, L. et al., “Modelling Myc inhibition as a cancer therapy,” Nature, vol. 455 (7213):679-683 (2008).
[cited by applicant]
Soucek, L. et al., “Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis,” Cancer Research, American Association of Cancer Research, vol. 62 (12):3507-3510 (2002).
[cited by applicant]
Su, X., et al., “In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles”, Molecular Phamaceutics, vol. 8: 744-787 (2011).
[cited by applicant]
Sullenger, B. et al., “Emerging clinical applications of RNA,” Nature, vol. 418: 252-258 (2002).
[cited by applicant]
Supplementary European Search Report, European Application No. 15821578.0, dated Sep. 3, 2018, 10 pages.
[cited by applicant]